Hematology Research Center, Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Expert Rev Hematol. 2023 Apr;16(4):289-295. doi: 10.1080/17474086.2023.2174520. Epub 2023 Feb 12.
Hairy cell leukemia (HCL) is an indolent chronic lymphoproliferative disorder and first-line treatment with either intravenous or subcutaneous cladribine generally leads to long-lasting remissions.
All 131 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 91 months. Data is from 2007 to 2020. We evaluated the response rate to cladribine as the first line and the response rate to cladribine with or without rituximab in relapsed patients. Further, we assessed relapse-free survival, complications, and secondary malignancy.
After a median follow-up of 91 months, the recurrence rate was 24%. The 5-year and 10-year RFS rates were 85% and 66%, respectively. Adding rituximab to 2-CDA leads to a better response rate than just cladribine (90% vs. 27.3%, p-value = 0.002) in the relapsed patients.
HCL patients have long-term survival when cladribine is the first line of treatment. Furthermore, adding rituximab to cladribine leads to a higher response rate.
毛细胞白血病（HCL）是一种惰性慢性淋巴增殖性疾病，一线治疗采用静脉或皮下 cladribine 通常可获得持久缓解。
对 131 例毛细胞白血病（HCL）患者进行分析，中位随访时间为 91 个月。数据来自 2007 年至 2020 年。我们评估了 cladribine 作为一线治疗的反应率，以及 cladribine 加或不加利妥昔单抗在复发患者中的反应率。此外，我们评估了无复发生存率、并发症和继发性恶性肿瘤。
中位随访 91 个月后，复发率为 24%。5 年和 10 年 RFS 率分别为 85%和 66%。在复发患者中，与 cladribine 相比， cladribine 加利妥昔单抗的反应率更高（90% vs. 27.3%，p 值=0.002）。
当 cladribine 作为一线治疗时，HCL 患者具有长期生存。此外， cladribine 加利妥昔单抗可提高反应率。
